Advanced Nasopharyngeal Carcinoma Patients Have Similar Outcomes with Neoadjuvant Chemo
the Cancer Therapy Advisor take:
In a study recently published in the journal BMC Cancer, researchers from the National Cheng Kung University Hospital in Taiwan reviewed the long-term outcomes of 128 patients with confirmed locally advanced nasopharyngeal carcinoma (LA-NPC) in Epstein-Barr virus infection endemic areas.
These patients received either neoadjuvant chemotherapy followed by radiotherapy (NACT) or concurrent chemoradiotherapy (CCRT; consisting of 3-week cycles of cisplatin or 4-week cycles of cisplatin and fluorouracil). The first failure site, disease free survival (DFS), overall survival (OS), and other prognostic factors were analyzed. Thirty-eight (30%) of the 128 patients received NACT, and those patients with advanced nodal disease and advanced clinical stage (stage IVA-IVB) were more likely to enroll in the NACT group.
When NACT to CCRT, patients who received NACT had similar 5-year DFS and OS (51.5% vs 65.1%, p = 0.28 and 71.7% vs 74.3%, p = 0.91, respectively); however, in those patients who were recurrence-free in the first 2 years after treatment, those who received NACT treatment had worse locoregional control compared with patients who received CCRT (hazard ratio =2.57, 95% CI: 1.02 to 6.47, p =0.046).
The authors concluded that although the two treatments had similar outcomes, patients treated with NACT should be followed-up closely because they are more likely to develop locoregional failure than patients receiving CCRT.
Patients treated with neoadjuvant chemotherapy should be followed-up closely.
This research compared the long–term outcomes between LA–NPC patients treated with neoadjuvant chemotherapy followed by radiotherapy (NACT) and those treated with concurrent chemoradiotherapy (CCRT). For LA–NPC, both CCRT and NACT were similarly efficacious treatment strategies in terms of long–term disease control and survival probability.
Close locoregional follow–up is recommended for patients receiving NACT, because these patients are more prone to develop locoregional failure than patients receiving CCRT.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer